dailynewsnblog
Researchers are taking a closer look at how medications used to treat diabetes may also influence cancer. While diabetes itself has long been associated with higher cancer risk, scientists are now investigating whether diabetes drugs play a direct role beyond controlling blood sugar levels and body weight. A recent review examines how widely used treatments such as metformin, SGLT2 inhibitors, and GLP-1 receptor agonists may affect cancer growth by changing how cells multiply, how the immune system responds, and how inflammation develops. These insights point to possible new treatment strategies while also highlighting how much remains unknown.
Type 2 Diabetes (T2DM) has been linked to a higher likelihood of developing several types of cancer, including liver, colorectal, and breast cancer. Managing blood glucose and body weight remains essential for people with diabetes, but growing evidence suggests these factors alone do not fully explain the increased cancer risk. This has led scientists to explore how diabetes medications themselves might influence cancer, either by reducing risk or, in some cases, creating unintended effects. Understanding this connection could help clarify how diabetes treatments fit into cancer prevention and care, though further research is still needed to unravel the underlying biology.
A Closer Look at Diabetes Drugs and Cancer Biology
Published on December 10, 2025, in Precision Clinical Medicine, this review brings together current research on how anti-diabetic medications interact with cancer. The study was led by researchers at Peking University People’s Hospital and moves beyond the traditional focus on blood sugar control and weight management. Instead, it examines how drugs such as metformin, SGLT2 inhibitors, and GLP-1 receptor agonists may influence cancer progression through multiple biological pathways. The findings add depth to the ongoing discussion about how diabetes treatments can affect cancer outcomes in complex and sometimes unexpected ways.
What the Evidence Shows About Specific Medications
The review analyzes both laboratory and clinical studies that explore links between diabetes medications and cancer. Metformin, one of the most commonly prescribed diabetes drugs, appears to affect cancer through several mechanisms. These include strengthening anti-cancer immune responses and slowing tumor growth by altering the tumor microenvironment (TME). Metformin also influences major cellular pathways such as AMPK, mTOR, and PI3K/AKT, which help regulate cell growth, cell death, and the formation of new blood vessels.
Other diabetes medications show potential effects as well. SGLT2 inhibitors and GLP-1 receptor agonists have been associated with changes in cancer cell growth, reduced inflammation, and increased apoptosis. However, their impact is not consistent across all cancers or drugs. For instance, metformin has shown encouraging results in lowering the risk of colorectal and liver cancers, while its role in breast cancer remains unclear. The review emphasizes that each medication works differently and that more clinical trials are needed to confirm these findings and better understand their role in cancer treatment.
Expert Perspective on Unanswered Questions
Dr. Linong Ji, a leading researcher in this area, notes that important questions remain. “While anti-diabetic medications are crucial in managing diabetes, their broader effects on cancer are still not fully understood. This review sheds light on the intricate mechanisms through which these drugs may influence cancer progression. However, the evidence is mixed, and we must continue to investigate the long-term impacts of these medications in cancer patients, as well as the potential for developing targeted therapies based on these findings.”
Toward More Personalized Treatment Strategies
The review highlights the growing importance of personalized medicine for patients who have both diabetes and cancer. A clearer understanding of how specific diabetes drugs affect cancer could help doctors tailor treatments more effectively, improving prevention strategies and patient outcomes. The findings also support the need for future clinical trials to test how existing diabetes medications might be refined for cancer therapy or used alongside standard treatments. Insights into drugs such as metformin may also guide public health efforts, especially for populations facing higher risks of both diabetes and cancer.
This work was supported by the 2024 National Clinical Key Specialty Construction Program of China (Department of Endocrinology, Peking University People’s Hospital) with support from the central government budget, the Noncommunicable Chronic Diseases National Science and Technology Major Project (grant Nos. 2023ZD0508200, 2023ZD0508205), the Clinical Medicine Plus X Young Scholars Project of Peking University (grant No. PKU2025PKULCXQ025), and the Fundamental Research Funds for the Central Universities.
